Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment

• Published in: World journal of gastroenterology : WJG Vol. 12; no. 25; pp. 4061 - 4063
• Main Authors: Ke, Chang-Zheng, Chen, Yue, Gong, Zuo-Jiong, Meng, Zhong-Ji, Liu, Li, Ren, Ze-Jiu, Zhou, Zuo-Hua
• Format: Journal Article
• Language: English
• Published: United States Department of Infectious Diseases, Taihe Hospital Affiliated to Yunyang Medical College, Shiyan 442000, Hubei Province, China%Department of Infectious Diseases, Renmin Hospital Affiliated to Wuhan University, Wuhan 430060, Hubei Province, China%Clinical Laboratory, Taihe Hospital Affiliated to Yunyang Medical College, Shiyan 442000, Hubei Province, China 07.07.2006; Baishideng Publishing Group Co., Limited
• Subjects: Adolescent; Adult; DNA, Viral - blood; Female; Hepatitis B virus - isolation & purification; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Humans; Lamivudine - therapeutic use; Leukocytes, Mononuclear - chemistry; Leukocytes, Mononuclear - virology; Male; Middle Aged; Rapid Communication; Reverse Transcriptase Inhibitors - therapeutic use; 乙型病毒肝炎; 单核细胞; 外周血; Peripheral blood mononuclear cells; Lamivudine; Hepatitis B virus; DNA
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v12.i25.4061

AIM： To study the dynamic changes of hepatits B virus （HBV） DNA in serum and peripheral blood mononuclear cells （PBMCs） of patients after lamivudine therapy. METHODS： A total of 72 patients with chronic HBV infection were included in this study. All patients were confirmed to have the following conditions： above 16 years of age, elevated serum alanine amonotransferase （ALT）, positive hepatitis B e antigen （HBeAg）, positive HBV DNA in serum and PBMCs, negative antibodies against HAV, HCV, HDV, HEV. Other possible causes of chronic liver damages, such as drugs, alcohol and autoimmune diseases were excluded. Seventy-two cases were randomly divided into lamivudine treatment group （n = 42） and control group （n = 30）. HBV DNA was detected both in serum and in PBMCs by fluorescence quantitative polymerase chain reaction （PCR）, during and after lamivudine treatment. RESULTS： In the treatment group, HBV DNA became negative both in serum and in PBMC, of, 38 and 25 out of 42 cases respectively during the 48 wk oflamivudine treatment, the negative rate was 90.5% and 59.5% respectively. In the control group, the negative rate was 23.3% and 16.7% respectively. It was statistically significant at 12, 24 and 48 wk as compared with the control group （P 〈 0.005）. The average conversion period of HBV DNA was 6 wk （2-8 wk） in serum and 16 wk （8-24 wk） in PBMC. CONCLUSION： Lamivudine has remarkable effects on HBV replication both in serum and The inhibitory effect on HBV DNA in PBMCs than that in serum inhibitory in PBMCs. is weaker